Showing 5831-5840 of 10135 results for "".
- FDA Accepts NDAs for Review of Binimetinib And Encorafenib for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-accepts-ndas-for-review-of-binimetinib-and-encorafenib-for-advanced-braf-mutant-melanoma/2458058/The FDA has accepted Array BioPharma's New Drug Applications (NDAs) to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The FDA se
- FDA Expands Approval of Yervoy to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanomahttps://practicaldermatology.com/news/fda-expands-approval-of-yervoy-to-include-pediatric-patients-12-years-and-older-with-unresectable-or-metastatic-melanoma/2458113/The FDA has expanded the indication for Bristol-Myers Squibb's Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. Yervoy was evaluated in two trials of pediatric patients:
- FOREO's New At-Home Blue Light Acne Pen Hits the US and Canadahttps://practicaldermatology.com/news/foreos-new-at-home-blue-light-acne-pen-hits-the-us-and-canada/2458129/FOREO's blue-light acne pen is now available in 333 stores in the US and Canada with more to be added by September 2017. The FOREO ESPADA comprises 415 nanometers (nm) of blue light energy combined with red cross-hair targeting that converges as ESP
- Wontech's Pico Laser Gets FDA Nodhttps://practicaldermatology.com/news/wontechs-pico-laser-gets-fda-nod/2458146/The U.S. Food and Drug Administration (FDA) cleared WONTECH’s picosecond laser device for tattoo removal. PICOCARE removes tattoos in various colors in less time with 1064nm, 532nm, 595nm, and 660nm wavelengths and selectively removes pigment par
- Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch RHOFADEhttps://practicaldermatology.com/news/kristin-chenoweth-kicks-off-less-red-more-you-campaign-to-launch-rhofade/2458177/Emmy and Tony award-winning actress and singer Kristin Chenoweth is kicking off Allergan’s Rhofade "Less Red, More You" campaign. Chenoweth, who has rosacea, will begin a nationwide conversation about the condition while raising a
- Allergan Officially Adds Coolsculpting to Portfoliohttps://practicaldermatology.com/news/allergan-adds-coolsculpting-to-portfolio/2458207/It’s a done deal. Allergan now owns ZELTIQ® Aesthetics. Allergan acquired ZELTIQ® Aesthetics for approximately $2.4 billion in cash. ZELTIQ® stockholders approved the transaction during its stockholder meeting h
- FDA Approves New Eczema Drug Dupixenthttps://practicaldermatology.com/news/fda-approves-new-eczema-drug-dupixent/2458233/The FDA has approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Regeneron Pharmaceuticals, Inc.'s Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are n
- FDA Approved Juvéderm Vollure XC for Correction of Facial Wrinkles and Foldshttps://practicaldermatology.com/news/fda-approved-juvderm-vollure-xc-for-correction-of-facial-wrinkles-and-folds/2458241/The FDA has approved Allergan plc's Juvéderm Vollure XC for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21. In the US pivotal clinical trial, a majority (59 percent) of subjects saw improvement in moderate to severe na
- Venus Concept Launches Venus Velocity for Laser Hair Removalhttps://practicaldermatology.com/news/venus-concept-launches-venus-velocity-for-laser-hair-removal/2458314/Venus Concept is bringing a new hair removal laser to the US. Venus Velocity is a diode laser for hair removal, permanent hair reduction, and the treatment of razor bumps. The device has two modes of operation (SLIDE and PULSE), three changeable s
- FDA Approves RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For Persistent Facial Erythema Associated With Rosaceahttps://practicaldermatology.com/news/fda-approves-rhofade-oxymetazoline-hydrochloride-cream-1-for-persistent-facial-erythema-associated-with-rosacea/2458315/The FDA has approved Allergan's RHOFADE™ cream for the topical treatment of persistent facial erythema associated with rosacea in adults. Approval was based on two clinical studies that evaluated the primary efficacy endpoint on day 29. Among the estimated 16 million aAmericans